

Molecular Diagnostics

Part II: Regulations, Markets & Companies

By

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

November 2021

A Jain PharmaBiotech Report

AUTHOR'S BIOGRAPHY

Professor K. K. Jain is a neurologist/neurosurgeon with specialist qualifications including Fellowships of the Royal Colleges of Surgeons in Australia and Canada. He has trained, practiced and held academic positions in several countries including Switzerland, India, Iran, Germany Canada and USA. After retirement from neurosurgery, Prof. Jain remains a consultant in neurology. He is also working in the biotechnology/biopharmaceuticals industry and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently, he is the CEO of Jain PharmaBiotech.

Prof. Jain's 492 publications include 35 books (6 as editor + 29 as author) and 50 special reports, which have covered important areas in biotechnology, gene therapy and biopharmaceuticals. Books relevant to biotechnology and pharmaceuticals include "Role of Nanobiotechnology in Molecular Diagnostics" (2006), "Handbook of Nanomedicine" (Humana/Springer 2008; Chinese edition, Peking University Press 2011, 2nd ed Springer 2012, 3rd ed 2017), "Textbook of Personalized Medicine (Springer 2009; Japanese ed 2012; 2nd ed Springer 2015, 3rd ed 2021), "Handbook of Biomarkers" (Springer 2010; Chinese edition by Chemical Industry Press 2016, 2nd edition Springer 2017), "Handbook of Neuroprotection" (Springer 2011, 2nd ed 2019), "Drug-induced Neurological Disorders", 4th ed, Springer 2021), "Applications of Biotechnology in Cardiovascular Therapeutics" (Springer 2011), "Applications of Biotechnology in Neurology" (Springer 2013), and "Applications of Biotechnology in Oncology" (Springer 2014). He has edited "Drug Delivery to the Central Nervous System" (Humana/Springer 2010), "Drug Delivery Systems", 3rd edn (Springer 2019) and "Applied Neurogenomics" (Springer 2015). He has also written a "Textbook of Gene Therapy", which was the first book on this subject to be translated into the Chinese language. A book on gene therapy companies was published in 2000 by John Wiley & Sons. Updated material from both these books have been included in 2021 edition of a special report on Gene Therapy published by Jain PharmaBiotech Publications. Essentials of Personalized Medicine (in Russian, with Prof. K. Sharipov as co-author), 2019) is published by LITERRA Publishing House, Moscow. Currently, he is writing "The Handbook of Alzheimer Disease" to be published by Springer in 2022.

ABOUT THIS REPORT

Prof. Jain wrote the first commercial report on DNA Diagnostics covering scientific and commercial aspects in March 1995, which was published by PJB Publication, London. This was updated in 1997 as Molecular Diagnostics I and the next edition, Molecular Diagnostics II, was published in 1999 – both by Decision Resources Inc, USA. All the three versions of the reports were well accepted and sold widely. The current version was originally published by Jain PharmaBiotech in 2001 and is constantly updated since then. Not only was this the first such report on molecular diagnostics, it is the longest continuously published report (>25 years). It is also the most comprehensive and detailed report on this topic containing profiles of the largest number of companies involved in molecular diagnostics.

November 2021 (continuously published since 1995)
Copyright ©2021 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: <http://pharmabiotech.ch/>

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

12. Ethics, Patents and Regulatory issues.....	7
Introduction	7
Ethical concerns about genetic diagnosis.....	7
Ethical guidelines for molecular diagnostics	8
Ethical aspects of use of WGS for newborn and prenatal screening	9
Ethical aspects of direct-to-consumer genetic services	9
US public attitudes about genetic testing	10
Opinion of European geneticists about DTC genetic testing	10
Genetic testing for susceptibility to adult-onset cancer	11
Ethics of preimplantation genetic diagnosis	11
<i>Preimplantation genetic diagnosis to screen for hereditary diseases</i>	<i>11</i>
<i>PGD to test for susceptibility to cancer.....</i>	<i>12</i>
<i>PGD and stem cells</i>	<i>12</i>
Genetic research on stored tissues	12
Informed consent in clinical trials of in vitro devices	13
Concluding remarks about ethical issues	13
Insurance underwriting and gene tests	14
<i>Should genetic information be available to health insurers?.....</i>	<i>14</i>
<i>A need for the re-examination of current views.....</i>	<i>14</i>
<i>Genetic Information Nondiscrimination Act of US</i>	<i>15</i>
<i>Impact of the US health care reform bill on genetic testing issues</i>	<i>15</i>
Patents for molecular diagnostics.....	15
PCR patents	15
Patenting DNA sequences	15
US policy on gene patenting relevant to molecular diagnostics.....	16
The impact of disease gene patents on molecular diagnostics	17
Licensing problems associated with genetic testing	17
BRCA1 and BRCA2 gene patents	17
Role of the WHO in genetic testing standards	18
NIH's Genetic Testing Registry	19
Regulatory issues in the US	19
Assay Migration Studies for In Vitro Diagnostic Devices	19
Assessment of diagnostic accuracy	19
<i>Sensitivity and specificity</i>	<i>20</i>
<i>Documentation of diagnostic accuracy</i>	<i>21</i>
Discovery of incidental findings on genetic screening	21
Evaluation of companion diagnostics/therapeutic for cancer	22
FDA regulation of multivariate index assays	22
FDA guidance for IVDs to detect pathogens.....	23
FDA guidelines for devices to detect and differentiate HPV	24
FDA's Microarray Quality Control.....	24
FDA and point-of-care diagnosis	25
Genetic testing of rare disorders	25
Guidelines for developing omics-based tests.....	26
<i>Shared responsibility on oversight of omics-based tests.....</i>	<i>27</i>
Guidelines for use of sequencing for molecular diagnosis	27
<i>FDA oversight of next generation sequencing</i>	<i>28</i>
Quality control of molecular diagnostic laboratory procedures	29
Quality assurance of RNA expression profiling.....	29
Quality control of point-of-care tests	30
Regulation of IVD by the FDA	30
FDA guidance on research use and investigational use only IVDs	32
Regulation of in vitro companion diagnostics by the FDA.....	32
Regulation of in vivo diagnostics by the FDA.....	33
Regulation of laboratory developed tests.....	33
<i>Home-brew tests</i>	<i>33</i>
<i>Laboratory-developed tests used by Medicare recipients</i>	<i>33</i>
<i>Oversight of LDTs by the FDA.....</i>	<i>34</i>
<i>Alternative to FDA LDT guidance</i>	<i>35</i>
Regulatory aspects of FISH	36
Regulation of genetic testing	37
<i>Role of the FDA in genetic testing</i>	<i>37</i>
Regulation of direct-to-consumer genetic testing	37
<i>Need for regulatory oversight of DTC.....</i>	<i>37</i>
Regulatory issues concerning blood and plasma products.....	40
United States Diagnostics Standards	40

Regulation of in vitro diagnostics in the EU	41
EU regulations for testing of blood products	42
Regulation of genetic testing in EU	42
Evaluation of diagnostic laboratory tests in the UK	43
Pre-implantation genetic diagnosis in the UK	44
13. Markets for Molecular Diagnostics	45
Introduction	45
Methods for study of molecular diagnostic markets.....	45
The overall market for diagnostic technologies	46
Markets for in vitro diagnostics	46
Molecular diagnostic markets according to technologies	46
Marketing strategies according to technologies	47
Nucleic acid isolation market	47
Market for PCR-based tests	47
<i>Markets for PCR instrumentation.....</i>	<i>48</i>
<i>Markets for real-time PCR and qRT-PCR.....</i>	<i>48</i>
<i>PCR market players.....</i>	<i>49</i>
DNA sequencing market.....	49
Cost of NGS	49
Cytogenetic market.....	50
<i>Market for FISH technologies.....</i>	<i>50</i>
Biochip/microarray market.....	50
Biosensor market.....	51
Nanobiotechnology for molecular diagnostics.....	51
Markets for gene expression technologies	51
Reagents and other disposable laboratory materials	52
Market for immunochemistry diagnostic.....	52
Markets for tissue diagnostics.....	52
Molecular diagnostic markets according to therapeutic areas	52
Genetic disorders	53
Prenatal testing	54
<i>Non-invasive prenatal testing</i>	<i>54</i>
Cancer.....	54
<i>Potential markets for cancer diagnosis according to type of cancer.....</i>	<i>55</i>
Infectious diseases.....	56
<i>Diagnostics for COVID-19</i>	<i>58</i>
<i>Sexually transmitted diseases.....</i>	<i>58</i>
<i>Hospital-acquired infections.....</i>	<i>58</i>
<i>Testing for HIV drug resistance.....</i>	<i>59</i>
<i>Potential markets for avian influenza diagnostics</i>	<i>59</i>
Cardiovascular diseases.....	60
Neurological disorders	60
Food testing	60
Screening of blood for transfusion	61
Tissue typing for transplantation.....	61
Molecular diagnostic markets relevant to pharmaceutical industry	61
Molecular diagnosis and personalized medicine markets.....	61
Growth of markets relevant to personalized medicine	61
<i>Point-of-care market</i>	<i>62</i>
Marketing opportunities according to geographic areas	62
Unmet needs in molecular diagnostics.....	63
Major market trends	64
Markets according to home-brew and FDA-approved tests	64
Decentralization of molecular diagnostics	64
Direct-to-consumers healthcare testing	65
Point-of-care testing.....	65
Development of personalized medicine	65
<i>Cost of sequencing the human genome.....</i>	<i>66</i>
<i>Cost of genotyping.....</i>	<i>66</i>
<i>Marketing companion diagnostics for personalized medicine</i>	<i>67</i>
Development of low-cost tests.....	67
Simplification of test procedures	67
Increasing role of proteomics in clinical diagnostics	68
Forensic and legal applications	68
Veterinary molecular diagnostics.....	68
Marketing strategies.....	69
Role of alliances in commercialization of molecular diagnostics	69
<i>Acquisitions vs collaborations</i>	<i>69</i>
<i>Analysis of collaborations in molecular diagnostics</i>	<i>74</i>
<i>Licensing of the technologies.....</i>	<i>74</i>

Strategies related to laboratory facilities and technologies	74
Strategies relevant to the healthcare system	74
<i>Cost-Benefit studies</i>	75
<i>Genetic susceptibility testing</i>	75
<i>Preventive medicine strategies</i>	75
<i>Targeting treatable and common diseases</i>	76
Information/education	76
<i>Physician education</i>	76
<i>Patient education</i>	77
<i>European diagnostic information platform</i>	77
Regulatory strategies	77
Merger of in vitro and in vivo diagnostics	78
Integration of diagnostics with therapeutics	78
Diagnostic applications in clinical trials	78
Prospects for development of new technologies	78
Drivers for the development of molecular diagnostics	79
Factors slowing the development of molecular diagnostics	79
Cost of sequencing the human genome	79
Challenges and future prospects for diagnostic applications of sequencing	80
US organizations for advancing molecular diagnostic industry	81
<i>AdvaMedDx</i>	81
European projects for improving molecular diagnostics	81
<i>European Consortium for developing new DNA analysis tools</i>	81
<i>EU project for improvement of IVD tools procedures</i>	82
<i>Genetic knowledge parks in the UK</i>	82
Molecular diagnostic opportunities in defense against bioterrorism	83
Molecular diagnostics for food safety	83
POC diagnostics for the Asian countries	84
14. Companies involved in molecular diagnostics	85
Introduction	85
Major players in molecular diagnostics	85
Profiles of selected companies	86
Collaborations	459

Tables

Table 13-1: Share of in vitro diagnostics in the global diagnostic market 2020-2030	46
Table 13-2: Molecular diagnostics markets according to technologies from 2020-2030	47
Table 13-3: PCR market 2020-2030	48
Table 13-4: Molecular diagnostics markets according to applications 2020-2030	52
Table 13-5: Markets in 2020 for tests to screen healthy persons for genetic disorders	53
Table 13-6: Markets in 2020 for molecular diagnostic screening tests for cancer	55
Table 13-7: Molecular diagnostic markets for selected cancers 2020-2030	55
Table 13-8: Markets value in 2020 for molecular diagnostic screening for infections	57
Table 13-9: Future markets for HAI diagnostics 2020-2030	58
Table 13-10: Growth of markets relevant to personalized medicine 2020-2030	62
Table 13-11: Molecular diagnostic markets according to geographical areas 2020-2030	62
Table 13-12: Molecular diagnostic markets according to home-brew and approved tests	64
Table 13-13: Marketing strategies for molecular diagnostics	69
Table 13-14: Acquisitions of molecular diagnostic companies	70
Table 13-15: Advantages of the integration of diagnostics with therapeutics	78
Table 14-1: Top ten players in molecular diagnostics	85
Table 14-2: Collaborations of companies in molecular diagnostics	459

Figures

Figure 13-1: Unmet needs in applications of molecular diagnostics	63
---	----